At a glance
ClinicalIndex Comparison RecordN/ACompleted· 502 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
KALETRA in Combination With New Substances (PROTEKT)
In Brief
An observational study for Human Immunodeficiency Virus. Completed, enrolled 502 participants.
Detailed Summary
The purpose of this study is to investigate the tolerability of Kaletra (lopinavir/ritonavir) in combination with new substances such as integrase inhibitors (INIs), C-C chemokine receptor type 5 (CCR5) antagonists, and new non-nucleoside reverse transcriptase inhibitors (NNRTIs), as there are many reasons (intolerability, complex resistant patterns or even personal reasons) which may result in a change from the daily clinical routine and lead to the use of a newly approved antiretroviral agent in combination with Kaletra.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus
Countries--
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedFeb 2010
Primary CompletionJan 2016
TodayJul 2026
First PostedFeb 26, 2010
Enrollment StartSep 1, 2008
Primary CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 16.3 years ago